Ever thought about launching an army from inside cancer cells? 🔬 A team led by Professor Peng Chen at Peking University recently unveiled a Trojan Horse-style intratumoural vaccine, iVAC, in Nature that forces 'immune-cold' tumors to unmask themselves and become prime targets for our T cell defenders. 💥
Why tumors hide from our immune system 😶
T cells are the immune system's special forces: they spot abnormal cells, eliminate them, and move on. Cancer cells… should be red flags. Yet some tumors grow stealth shields, like PD-L1 molecules that say Don't attack me to T cells. The result? 'Immune-cold' tumors that slip by, leaving patients without effective immunotherapies. 🚫⚔️
The Trojan Horse breakthrough 🐴🔓
Chen's team has been fine-tuning targeted protein degradation since 2021. But this time, they took it up a notch. Enter iVAC – a tiny 18 kDa molecule built to infiltrate solid tumors. Here's the 3-in-1 magic:
- 🎯 PD-L1 Targeting: A covalent nanobody binds the tumor's 'don't shoot' signal.
- 🔄 Forced Internalization: iVAC drags PD-L1 into the lysosome, the cell's recycling center.
- 📢 Antigen Exposure: Degraded bits of tumor proteins appear on the surface like neon signs, screaming 'Hit me!' to T cells.
What's next? 🛣️
With promising lab results, the team is gearing up for preclinical trials. If iVAC delivers in vivo, it could rewrite the immunotherapy playbook, turning cold tumors hot and giving new hope to patients. 🌟
Stay tuned for more updates as this biotech revolution unfolds! 🚀
Reference(s):
cgtn.com
